Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PBI-1402

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
BACKGROUND: PBI-1402 reduces the need for transfusion and increases hemoglobin (Hb) level and red blood cell count (RBC) in… Expand
Is this relevant?
2011
2011
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Background: PBI-1402 reduces the need for transfusion… Expand
Is this relevant?
2008
2008
(-)-Epigallocatechin gallate, (-)-Gossypol; Ad.hIFN-beta, AF-37702, Agatolimod sodium, Agomelatine, Alvocidib hydrochloride, ARC… Expand
Is this relevant?
2008
2008
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… Expand
Is this relevant?
2007
2007
Background: PBI-1402 is a novel orally active low molecular weight synthetic compound with erythropoiesis stimulating activity… Expand
Is this relevant?
2006
2006
PBI-1402 is a non-toxic, well-defined low molecular weight synthetic hematopoietic growth stimulant. PBI-1402 promotes the… Expand
Is this relevant?
2006
2006
PBI-1402 is an orally active low molecular weight synthetic compound which is currently in a phase Ib/II clinical trial in… Expand
Is this relevant?
2006
2006
Erythropoiesis is regulated by an intricated network of transcription factors and other molecules that mediate differentiation of… Expand
Is this relevant?
2006
2006
The goal of this study was to determine the potential of PBI-1402, a compound that was shown to provide radio- and… Expand
Is this relevant?
2005
2005
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… Expand
Is this relevant?